The use of tissue engineering and cell therapy technologies in the treatment of orthopedic and spine disorders and trauma represents a significant current and future market globally. These products, from autologous and other cell/tissue transplants, cell matrices, biomaterials and other products are employed in treatment of non-union fractures, cartilage repair, ligament repair, vertebral disc repair, bone grafting and other emerging applications.
It is an active current market, with many participating companies (with products in development and on the market):
3DM Inc., Aastrom Bioscience Inc., Arteriocyte Medical Systems, Inc., BeFutur Biotechnologies, Bio Nova International, Biocomposites, Biocoral Inc., Biomet, Inc., BioMimetic Therapeutics, BioSyntech, BioTissue Technologies GmbH, co.don AG, ConMed Linvatec Biomaterials, Inc., Cytomatrix LLC, DePuy, Exactech, Inc., Fidia Advanced Biopolymers / Anika Therapeutics, Inc., Forticell Bioscience, Inc., Genzyme Biosurgery, Geron Corporation, Inion Ltd, InnovaCell Biotechnologie GmbH, Integra LifeSciences Inc., ISTO Technologies Inc., Johnson & Johnson Inc. / DePuy, Kensey Nash, Kerecis EHF, LifeCell Inc. (Kinetic Concepts), Medtronic, Mesoblast Limited, Musculoskeletal Transplant Foundation, Organogenesis Inc., Orthovita, Osiris Therapeutics Inc., Osteotech, Pioneer Surgical Technologies, ProChon Biotech, Ltd., ReGen Biologics Inc., RTI Biologics, Inc., Serica Technologies, Inc. (Allergan), Smith & Nephew Ltd., SpineSmith, LP, Stem Cell Therapy International, Inc. / Histostem, Stryker Corporation, Synovis Life Technologies, Inc., TEI Biosciences Inc., Tepha Inc., TheraCell Inc., ThermoGenesis, Corp., TiGenix N.V., TETEC (Tissue Engineering Technologies AG/B.Braun/Aesculap), and Zimmer, Inc.
Globally, the U.S. represents the most significant country/regional market in current sales, but higher growth is projected for markets outside the U.S.: